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Proline-directed phosphorylation is regulated by the
prolyl isomerase Pin1, which plays a fundamental
role in driving breast cancer stem-like cells (BCSCs).
Rab2A is a small GTPase critical for vesicle traf-
ficking. Here, we show that Pin1 increases Rab2A
transcription to promote BCSC expansion and
tumorigenesis in vitro and in vivo. Mechanistically,
Rab2A directly interacts with and prevents dephos-
phorylation/inactivation of Erk1/2 by the MKP3
phosphatase, resulting in Zeb1 upregulation and
b-catenin nuclear translocation. In cancer cells,
Rab2A is activated via gene amplification, mutation
or Pin1 overexpression. Rab2A overexpression or
mutation endows BCSC traits to primary normal
human breast epithelial cells, whereas silencing
Rab2A potently inhibits the expansion and tumori-
genesis of freshly isolated BCSCs. Finally, Rab2A
overexpression correlateswith poor clinical outcome
in breast cancer patients. Thus, Pin1/Rab2A/Erk
drives BCSC expansion and tumorigenicity, suggest-
ing potential drug targets.
INTRODUCTION
Cancer stem cells (CSCs) or tumor-initiating cells (TICs) have
been hypothesized to retain the capacity of self-renewal to
regenerate the bulk of a heterogeneous tumor. The CSC concept
has important implications for understanding the molecular
mechanisms of cancer progression and identifying targets for
cancer therapeutics, since CSCs are thought to be responsible
for tumor initiation, progression, metastasis, relapse, and drug
resistance (Liu and Wicha, 2010). Thus, the elucidation of CSC
regulatory mechanisms and the identification of targets to erad-
icate the CSC compartment in a tumor may be essential to
achieve long-term remission of cancer (Liu and Wicha, 2010).
An increasing number of regulators of breast cancer stem-like
cells (BCSCs), notably transcription factors including Zeb1 andb-catenin, have been identified (Reya and Clevers, 2005; Wellner
et al., 2009). These transcription modulators are further regu-
lated by upstream signaling pathways. For example, Erk
signaling has been shown to regulate BCSCs by increasing tran-
scription of Zeb1 and nuclear accumulation of unphosphorylated
(active) b-catenin (Chang et al., 2011; Shin et al., 2010). However,
regulatory pathways upstream of Erk signaling that regulate
BCSCs are still not fully understood.
Among the small GTPase superfamily, Ras has been shown to
induce the epithelial-mesenchymal transition (EMT) and confer
CSC traits to breast cells in vitro and in vivo (Liu et al., 2009;
Shin et al., 2010). Rac1 is involved in CSC maintenance in non-
small cell lungadenocarcinomaandglioma, aswell as in intestinal
progenitor and stem cell expansion (Akunuru et al., 2011; Myant
et al., 2013;Yoonet al., 2011).However, the rolesof otherGTPase
family members in CSCs in solid tumors are yet to be elucidated.
Protein phosphorylation on certain serine or threonine resi-
dues preceding a proline (pSer/Thr-Pro) is a central signaling
mechanism in cell proliferation and transformation (Blume-Jen-
sen and Hunter, 2001). We have shown that certain pSer/Thr-
Pro motifs exist in two distinct conformations, cis and trans,
and identified Pin1, a unique prolyl isomerase that binds to and
catalyzes cis/trans isomerization of specific pSer/Thr-Pro motifs
(Lu et al., 1996; Lu and Zhou, 2007; Yaffe et al., 1997). Pin1 in-
duces conformational changes of these Ser/Thr-Pro motifs after
phosphorylation, which now can be visualized by proline isomer-
specific antibodies (Nakamura et al., 2012). Importantly, Pin1 is
overexpressed and/or activated in human cancers and plays a
critical role in breast cancer development in vitro and in vivo
(Chen et al., 2013; Lee et al., 2011; Lu and Zhou, 2007; Lu and
Hunter, 2014). Recently, we and others have found that Pin1 is
increased in human BCSCs and plays a fundamental role in
driving BCSCs and tumorigenesis (Luo et al., 2014; Rustighi
et al., 2014). Although Pin1 has been reported to activate and
inactivate a large subset of key oncogenes and tumor suppres-
sors, respectively (Lu and Zhou, 2007; Lu and Hunter, 2014), the
downstream target of Pin1 in BCSCs is largely unknown.
In searching for Pin1 downstream targets in BCSCs using
genome-wide expression profiling, we identified Rab2A, a small
GTPase mainly localized to the ER-Golgi intermediate compart-
ment (ERGIC) that is essential for membrane trafficking betweenCell Reports 11, 111–124, April 7, 2015 ª2015 The Authors 111
the ER and Golgi apparatus, but with no known function in can-
cer or CSCs (Stenmark, 2009; Tisdale and Balch, 1996). We
show that as a Pin1 transcriptional target, Rab2A is a BCSC-
promoting gene that enhances tumorigenesis via activating Erk
signaling. Thus, the Pin1/Rab2A/Erk axis drives BCSC expan-
sion and tumorigenicity, providing attractive targets in BCSCs
for cancer therapy.
RESULTS
Genomic Profiling Analyses Identifies Rab2A as a Pin1
Downstream Gene
We have previously demonstrated a fundamental role of Pin1 in
regulating human BCSCs and mouse mammary stem cells
(MaSCs) (Luo et al., 2014). To elucidate the underlying molecular
mechanisms, we analyzed the effects of Pin1 knockout (KO) on
gene expression in mouse mammary epithelial cells (MECs).
Global expression profiling of Lin MECs from Pin1 KO and
wild-type (WT) littermates identified 1,723 genes that were
downregulated in both Pin1 KOmice (Figures 1A and 1B; Tables
S1 and S2). To narrow down the list of Pin1-regulated genes, we
compared MEC gene expression with that of neurospheres pre-
pared from the same mice (Figure 1B; Table S3). Although
comparing expression profiles of stem cells from WT and Pin1
KO mice may be a better approach, the MaSC-enriched
LinCD24+CD29+ or LinCD24medCD49fhi populations are very
small in Pin1 KO mice (Luo et al., 2014), which made it difficult
to get enough RNA from each mouse. As an alternative
approach, we re-analyzed two published expression profiling
datasets of mouseMaSCs and BCSCs (Stingl et al., 2006; Zhang
et al., 2008) and compared them with our expression profiling
of LinMECs and neurons from Pin1 KO andWTmice. We iden-
tified 14 genes downregulated in both Pin1 KO MECs and
neurons and upregulated in either MaSCs or BCSCs (Figure 1C;
Table S4).
To validate thesecandidate genes,weusedqRT-PCR todeter-
mine the effects of Pin1 knockdown (KD) on their expression in six
human breast cell lines. Rab2A, Lamp2, and Magi3 were down-
regulated in more than five KD cell lines (Figures 1D and S1A).
Pin1 KD also reduced Rab2A protein in all six different cell lines
(Figure S1B). To test the effects of these genes in BCSCs, we
silenced their expression using two different small hairpin RNAs
(shRNAs) in MCF10A cells and examined the CD24CD44+ pop-
ulation, which enriched human BCSCs (Al-Hajj et al., 2003).
Rab2A KD consistently decreased the CD24CD44+ population
(Figure S1C), suggesting a requirement of Rab2A for BCSCmain-
tenance. Thus, we focused on Rab2A as a Pin1 target.
In the promoter region of Rab2A, there are two putative AP-1
binding sites (1,293 and 890) (Figure S1D). Notably, Pin1 ac-
tivates transcription factors c-Jun and c-Fos to increase AP-1
activity (Monje et al., 2005;Wulf et al., 2001). We therefore tested
whether Pin1 regulated Rab2A transcription. In the reporter
assay, we found that Pin1 overexpression enhanced Rab2A
transcription in a dose-dependent manner (Figure 1E). Deletion
analysis suggested that Pin1 appeared to act on the distal
AP-1 site, but not the proximal site (Figure 1F). To confirm that
Pin1 regulates Rab2A transcription through AP-1, we first exam-
ined whether Pin1 bound to Rab2A promoter by chromatin112 Cell Reports 11, 111–124, April 7, 2015 ª2015 The Authorsimmunoprecipitation (ChIP) using cells transfected with Pin1
expression plasmid. Compared to control immunoglobulin G,
anti-Pin1 antibodies showed appreciable binding to the 1,293
locus, as assayed by qPCR (Figure 1G). Next, we used a c-Jun
antibody to perform the ChIP assay in human mammary large-T
and hTERT transformed epithelial cells (HMLE)-Ras cells,
because Pin1 binds to c-Jun, which is phosphorylated by JNK
and cooperates with Ras to increase the transcriptional activity
of c-Jun toward its target genes (Wulf et al., 2001). Indeed,
c-Jun specifically associated with the 1,293 locus in the
Rab2A promoter (Figure 1H). Moreover, a sequential ChIP (re-
ChIP) analysis using c-Jun antibody followed by Pin1 antibody
demonstrated that both proteins were present in the same com-
plex on the 1,293 locus (Figure 1I). Thus, Pin1 activates Rab2A
transcription through AP-1 and increases its protein levels in
breast cancer cells.
Rab2A Is a Major Mediator of Pin1 in Regulating BCSC
Function
To investigate whether Rab2A is a functional downstream target
of Pin1, we knocked down Rab2A in control or Pin1-overex-
pressing HMLE cells to examine whether Rab2A mediates the
action of Pin1 in BCSCs (Figure 1J). As shown previously (Luo
et al., 2014), Pin1 overexpression drastically increased the pop-
ulation of BCSC-enriched CD24CD44+ cells by 8- to 9-fold
above that of the vector control-infected HMLE cells (Figures
1K and 1L). Rab2A KD greatly reduced the size of the
CD24CD44+ population in vector control HMLE cells (Figures
1K and 1L), as did Pin1 KD (Luo et al., 2014). In Pin1-overex-
pressing cells, Rab2A KD partially decreased the abundance
of CD24CD44+ cells (Figures 1K and 1L). We then performed
a mammosphere-forming assay, which measures the frequency
of early progenitor/stem cells and BCSCs (Dontu and Wicha,
2005). Rab2A KD decreased mammosphere formation by both
vector control and Pin1-overexpressing HMLE cells (Figure 1M).
Thus, Rab2A was required to sustain the BCSC-enriched popu-
lation in control cells and Pin1-overexpressing cells.
Recently, we showed that Pin1 overexpression induces EMT
in HMLE cells (Luo et al., 2014). Strikingly, Rab2A KD in Pin1-
overexpressing cells reverted the EMT phenotype. After Rab2A
KD, Pin1-overexpressing HMLE cells changed to the epithelial
morphology (Figure 1N), with increased E-cadherin and
decreased N-cadherin, vimentin, and fibronectin levels (Fig-
ure 1O). Cell migration, a property associated with the EMT,
was also greatly attenuated by Rab2A KD in Pin1-overexpress-
ing cells in wound-healing (Figure S2A) and transwell migration
assays (Figure S2B). Thus, Rab2A is a major mediator of Pin1
in regulating BCSC function.
Rab2A Is Amplified in Human Cancers and Its
Overexpression Increases the BCSC-Enriched
Population and Tumorigenicity
To determine more directly the role of Rab2A in breast cancer,
we first checked Rab2A gene alterations in cancers in the cBio
Cancer Genomics Portal (Cerami et al., 2012). Significantly,
Rab2A gene amplification occurs in a wide range of human can-
cers, with the highest frequency of 9.5% (72 of 760) in invasive
breast carcinoma patients (Figure 2A). Importantly, Rab2A
Figure 1. Genome-wide Expression Profiling Identifies Rab2A as a Pin1 Target that Promotes BCSC Expansion and EMT
(A) Hierarchical cluster of the microarray data of the Lin population of mammary epithelial cells in two pairs of WT and Pin1 KO littermates.
(B) Genomic profiling identified 14 potential target genes that were downregulated in Pin1 KO MECs and neuron cells (NCs) but upregulated in mouse MaSCs
or BCSCs.
(C) Heatmap depicting the fold changes of 14 candidate genes, which were downregulated in Pin1 KO cells (presented by KO/WT ratio) but upregulated in either
mouse MaSCs or BCSCs (presented by SC/non-SC ratio).
(D) Pin1 KD reduced Rab2A mRNA in human breast cancer lines, as assayed by real-time PCR.
(E and F) Pin1 activated the Rab2A promoter in a dose-dependent manner.
(G–I) Both Pin1 and c-Jun bound to the Rab2A promoter, as shown byChIP andRe-ChIP analyses. Real-time PCRdatawere calibrated to immunoglobulin G (IgG)
control and normalized with sample inputs of chromatin harvested prior to immunoprecipitation.
(J) Rab2A was knocked down in vector control and Pin1-overexpressing HMLE cells, as confirmed by immunoblot.
(K and L) Rab2A KD in HMLE cells reduced the CD24CD44+ population and suppressed the ability of Pin1 overexpression to increase the CD24CD44+
population.
(M) Rab2A KD in HMLE cells reducedmammosphere-forming activity and impaired the ability of Pin1 overexpression to increasemammosphere-forming activity.
(N and O) Rab2A KD impaired the ability of Pin1 overexpression to induce the EMT in HMLE cells, as shown by cell morphology (N) or upregulation of E-cadherin
and downregulation of N-cadherin, fibronectin, and vimentin by qRT-PCR (O). Scale bar represents 100 mm.
In all panels, error bars represent SD of three independent experiments. See also Figures S1 and S2.mRNA levels increase significantly with increasing gene copy
number in invasive breast carcinomas (p = 1.56E84) and others
(Figure S3A). Moreover, Rab2A amplification is independent of
MYC on 8q, according to Tumorscape software (Beroukhim
et al., 2010).
We then overexpressed Rab2A in control shRNA or Pin1 KD
HMLE cells (Figure 2B). Moderate Rab2A overexpression (two
to three times the endogenous level) not only strongly increasedthe CD24CD44+ population (Figures 2C and S3B) andmammo-
sphere formation (Figure 2D) in control HMLE cells but also
significantly rescued the defects in BCSC-associated properties
in Pin1 KD cells (Figures 2C and 2D). Like Pin1 overexpression
(Luo et al., 2014), ectopic Rab2A expression also induced EMT
in HMLE cells, which developed an elongated fibroblast-like
morphology with decreased cell-cell contact (Figure 2E). The
EMT phenotype was further confirmed by decreased E-cadherinCell Reports 11, 111–124, April 7, 2015 ª2015 The Authors 113
Figure 2. Rab2A Is Amplified in Human Cancers, Its Overexpression Expands BCSCs and Tumorigenicity, and the Cancer-Derived Rab2A
Q58H Mutant Has Reduced GTPase Activity
(A) Rab2A gene amplification in a wide range of human cancers reported in cBioPortal.
(B) Stable overexpression of Rab2A in Pin1 KD or control HMLE cells using retrovirus-mediated gene transfer, as determined by immunoblot.
(C) Overexpression of Rab2A in HMLE cells potently induced the CD24CD44+ population and rescued the phenotypes inhibited by Pin1 KD.
(D) Overexpression of Rab2A increased the mammosphere formation in control shRNA (shCtrl) HMLE cells and rescued the phenotypes inhibited by Pin1 KD.
(E and F) Overexpression of Rab2A potently induced the EMT in HMLE cells, as assayed by cell morphology (E) and real-time RT-PCR of the marker
expressions (F).
(G and H) Rab2A overexpression increased tumorigenicity of BCSCs, while its KD impaired the ability of Pin1 overexpression to increase tumorigenicity of
BCSCs, as measured by a limiting-dilution tumor-initiation assay in nude mice. Two months later, mice were sacrificed and evaluated for tumor weight (G) and
tumor incidence (H).
(I) Q58 in Rab2A is evolutionally conserved across species.
(J and K) The Q58Hmutant displayed decreased GTP hydrolysis activity, compared to theWT Rab2A protein in the in vitro GTPase assay, as monitored by a-32P-
labeled GTP hydrolysis (J), and quantified by densitometry of three independent experiments (K).
(L) HMLE-Ras cells infected with Rab2A Q58H were more potent in forming tumors than those infected with WT Rab2A when overexpressed at the
endogenous levels.
In all panels, error bars represent SD of three independent experiments. See also Figure S3.and increased N-cadherin, vimentin, and fibronectin expression
in Rab2A-overexpressing cells (Figure 2F). Rab2A overexpres-
sion also enhanced cell migration in wound-healing (Figures
S3C and S3D) and transwell (Figures S3E and S3F) assays. To
further investigate whether Rab2A is sufficient to induce trans-
formation, we performed soft-agar colony formation assay on
Rab2A-overexpressing and control vector cells. Whereas con-
trol cells could hardly form colonies, Rab2A-overexpressing114 Cell Reports 11, 111–124, April 7, 2015 ª2015 The Authorscells robustly formed colonies (Figures S3G and S3H), further
supporting the oncogenic activity of Rab2A.
To evaluate the impact of Rab2A on tumor initiation, we as-
sessed the effects of Rab2A overexpression on tumor formation
by limiting dilution transplantation assays in nude mice. We used
HMLER cells, HMLE cells transformedwith V12H-Ras to form tu-
mors in nude mice (Elenbaas et al., 2001). No mice inoculated
with 1 3 104 control HMLER cells developed tumors, while
tumors developed in only two of eight mice inoculated with 105
control cells and three of six mice injected with 106 control cells
(Figures 2G and 2H). To examine whether endogenous Rab2A is
necessary for Pin1 to promote tumorigenicity of BCSCs, we
knocked down Rab2A in Pin1-overexpressing HMLER cells.
No tumors arose when 1 3 104 Pin1-expressing cells infected
with Rab2A shRNA (shRab2A) were injected into mice (Figures
2G and 2H). Although four of eight mice inoculated with 105
Pin1-shRab2A HMLER cells formed tumors, seven mice injected
with an equal number of Pin1 cells developed tumors. Similarly,
with Pin1 overexpression, 106 Rab2A KD cells formed fewer
tumors than control Pin1-overexpressing HMLER cells. Thus,
Rab2A inhibition potently impairs the ability of Pin1 to promote
BCSC tumorigenicity.
Rab2A Is Mutated in Human Cancers and the Q58H
Mutation Activates Rab2A
In addition to gene amplification, the Rab2A Q58H mutation has
been repeatedly identified in lung cancer patients in the cBio
Cancer Genomics Portal (Cerami et al., 2012). Given that Q58
is highly conserved in Rab2A genes across species (Figure 2I)
and most of the oncogenic mutants in the Ras superfamily affect
the enzyme’s ability to hydrolyze GTP (Schubbert et al., 2007),
we examined whether this mutation might affect the intrinsic
ability of Rab2A to hydrolyze GTP. Indeed, Rab2A Q58H hydro-
lyzed [a-32P]GTP to [a-32P]GDPmore slowly than the WT protein
(Figures 2J and 2K), resulting in more protein in the GTP-bound
state.
We then asked whether the Q58Hmutation might increase the
potency of Rab2A to expand the BCSC-enriched population. We
stably expressed Flag-Rab2A and its mutant using lentiviruses
with a less optimal Kozak sequence, resulting in proteins ex-
pressed similar to the endogenous level (Figure S3I). Interest-
ingly, Rab2A increased the CD24CD44+ percentage to 59%,
but Rab2A Q58H increased this population to 79% (Figure S3J).
To examine whether the Q58H mutation increased tumorige-
nicity, we examined tumor formation by injecting 13 106 HMLER
cells infected with vector control or Flag-Rab2A and Q58H
mutant expressing at the endogenous level into nude mice.
Although cells expressing WT Rab2A or its Q58Hmutant formed
tumors in all mice, the Q58H mutant tumors grew significantly
faster than WT controls (Figures 2L and S3K), suggesting that
the Rab2A Q58H mutant is more active in promoting tumor
growth than WT protein.
Erk1/2 Activation Is Essential for Rab2A to Regulate
BCSC Expansion
To understand howRab2A expands the BCSC-enriched popula-
tion, we examined whether Rab2A activates Erk1/2, which is
crucial for Ras to induce EMT and increase the CD24CD44+
population (Shin et al., 2010). After serum starvation and
EGF stimulation, Rab2A overexpression significantly increased
Erk1/2 activation monitored by p-Erk1/2 in a time-dependent
manner and also increased expression of Zeb1 (Figures 3A
and 3B), a transcription factor critical for inducing the EMT and
CD24CD44+ population (Shin et al., 2010; Wellner et al.,
2009). In contrast, Rab2A KD substantially impaired Erk1/2 acti-
vation (Figures 3A and 3B). We then asked whether the Q58Hmutation might increase Erk1/2 phosphorylation. When ex-
pressed at the endogenous level, the Q58H mutant induced
Erk1/2 activation even faster than WT Rab2A after EGF stimula-
tion (Figures 3C and 3D). Thus, Rab2A and its Q58H mutant
promote Erk1/2 activation. Next, we silenced Erk1 or 2 in
Rab2A-overexpressing HMLE cells (Figure 3E). Erk1 KD only
partially inhibited, but Erk2 KD substantially decreased, the abil-
ity of Rab2A overexpression to induce mammosphere formation
(Figure 3F) and the CD24CD44+ population (Figures 3G and
3H), indicating that Rab2A acts through Erk1/2 to maintain
BCSC-associated properties.
Rab2A Directly Interacts with and Prevents Erk1/2
Inactivation by MKP3
To elucidate how Rab2A overexpression or its Q58H mutation
activates Erk1/2, we first examined whether Rab2A co-localized
with Erk1/2. Overexpressing WT Rab2A not only activated
Erk1/2 but also surprisingly colocalized with activated Erk1/2
at the perinuclear region at 5min (Figure 4A) and 1 hr (Figure S4A)
after EGF stimulation. Overexpressing Rab2A Q58H at levels
similar to the endogenous level also activated and colocalized
with Erk1/2 (Figures 4A and S4A). Importantly, Rab2A and its
Q58H mutant colocalized with Erk1/2 at the ERGIC, as assayed
by ERGIC53 staining (Figure 4B). To examine whether Rab2A’s
vesicular trafficking function is associated with Erk activation,
we used brefeldin A (BFA) to block the trafficking from the ERGIC
to ER. As shown previously (Hauri et al., 2000), BFA treatment
damaged the ERGIC structure (Figure S4B) but did not obviously
affect Erk phosphorylation (Figure S4C), suggesting that Erk1/2
activation is likely to be independent of Rab2A’s trafficking
function.
The unexpected finding that Rab2A colocalizes with activated
Erk1/2 at the ERGIC suggested that Rab2A might directly
interact with Erk1/2. Indeed, we detected co-immunoprecipita-
tion of the endogenous Rab2A with total Erk1/2 in HMLE cells
by reciprocal co-immunoprecipitation (coIP) (Figure 4C). To
see whether Rab2A interacted with p-Erk1/2, we transfected
constitutively active MEK1 (AcMEK1) to increase p-Erk1/2 levels
and found that Rab2A interacted with p-Erk1/2 in the coIP assay
(Figure 4D). These results were further supported by our findings
that Rab2A contains a conserved common docking motif for
binding Erk (Tanoue et al., 2000) (Figure 4E) and that GST-
Rab2A pulled down Erk1/2 in cells (Figure 4F), as well as recom-
binant Erk1 or Erk2 in vitro (Figure S5A). To examine whether the
integrity of this dockingmotif is required for Rab2A to bind to Erk,
we substituted the known critical residues KR (mut1) or LXI
(mut2) or both residues (mut1/2) with Ala residues. Compared
to WT Rab2A, while either mut1 or mut2 markedly reduced bind-
ing to Erk, mutating both sequences completely abolished the
ability of Rab2A to bind to Erk (Figure 4F). Thus, Rab2A directly
interacts with Erk through the specific Erk docking sequence in
Rab2A.
Interestingly, the above conserved docking motif is also found
in MKP3 and MEK1. To examine whether Rab2A and MKP3 or
MEK1 compete to interact with Erk, HEK293 cells were co-trans-
fected with decreasing doses of myc-MKP3 or the constitutively
active hemagglutinin-MEK1 and a constant dose of Flag-Rab2A.
With decreasing amounts ofMKP3 expressed, more Erk1/2wereCell Reports 11, 111–124, April 7, 2015 ª2015 The Authors 115
Figure 3. Rab2A and Its Q58H Mutant Drive BCSC Expansion via Activating Erk1/2
(A and B) Rab2A regulated Erk1/2 phosphorylation and downstream Zeb1 expression. HMLE cells stably expressing Rab2A or shRNA or control vectors were
treated with EGF after serum starvation for the indicated time points to activate Erk1/2 and analyzed by immunoblot.
(C and D) Rab2A Q58H mutant activated Erk1/2 faster than WT Rab2A when overexpressed at the endogenous levels after EGF treatment. Arrowhead,
exogenous Flag-Rab2A; arrow, endogenous Rab2A.
(legend continued on next page)
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Figure 4. Rab2A Interacts with and Prevents Inactivation of Erk1/2 by MKP3
(A) Overexpressed Rab2A and its Q58Hmutant co-localized with p-Erk1/2. Stable HMLE cells were serum starved and then treated with 10 ng/ml EGF for 5 min.
Scale bar represents 10 mm.
(B) Rab2A and its Q58H mutant co-localized with ERGIC53. Scale bar represents 20 mm.
(C) Reciprocal coIP of endogenous Rab2A with Erk1/2. Lysates of HMLE cells were immunoprecipitated with Rab2A or Erk1/2 antibodies, followed by western
blot for Rab2A and Erk1/2, respectively.
(D) Rab2A immunoprecipitated with total Erk1/2 and p-Erk1/2 in HEK293 cells co-transfected with Flag-Rab2A and constitutive activated MEK1 (AcMEK1).
(E) The consensus Erk docking motifs were found in Rab2A and several other Erk binding partners. + and 4 represent basic and hydrophobic amino acids,
respectively. X represents any amino acids.
(F) Mutations in the Erk docking motif in Rab2A impaired its binding to Erk1/2.
(G) Rab2A andMKP3 competed to bind Erk1/2. Lysates of 293T cells transfected with decreasing doses of myc-MKP3 and a constant dose of Flag-Rab2A were
immunoprecipitated with M2 (Flag) antibody, followed by western blot for Erk1/2 and Flag-Rab2A.
(H) Rab2A competed with MKP3 and kept Erk1/2 in the phosphorylated status. 293T cells were transfected to express Rab2A, MKP3, and AcMEK1, which
induced p-Erk1/2 in serum-starved cells andwas largely reversed byMyc-MKP3 expression, whereas Flag-Rab2A expression dose-dependently restored Erk1/2
phosphorylation.
See also Figures S4 and S5.immunoprecipitated by Rab2A in a dose-dependent manner
(Figure 4G), suggesting that Rab2A competed with MKP3 to
bind Erk1/2 in vivo. However, unlike the MKP3 competition re-
sults, similar amounts of Erk1/2 were immunoprecipitated by
Flag-Rab2A even though decreasing amounts of MEK1 were ex-
pressed (Figure S5B). These results may be expected, because
although the dockingmotif of MEK is important for the ERK-MEK(E) Erk1 or Erk2 was knocked down by two independent lentivirus-mediated shR
(F) KD of Erk1/2, especially Erk2, prevented Rab2A from increasing the mammo
(G and H) KD of Erk1/2, especially Erk2, prevented Rab2A from increasing the C
In all panels, error bars represent SD of three independent experiments.interaction, there are other mechanisms to ensure the activation
of Erk byMEK1, such as scaffold protein facilitation and theMEK
catalytic site interacting with the Erk activation loop (Roskoski,
2012).
The above results suggest that Rab2A might prevent Erk1/2
dephosphorylation by competing with MKP3 for Erk1/2 binding.
To test this possibility, we transfected HEK293 cells with MKP3NAs in Rab2A-overexpressing cells.
sphere-forming capability.
D24CD44+ population.
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and the constitutively active MEK1 as well as different amounts
of epitope-tagged Rab2A. Expression of the active MEK1
induced Erk1/2 phosphorylation even in serum-starved cells,
and this was largely reversed by myc-MKP3 expression (Fig-
ure 4H). However, Flag-Rab2A expression restored Erk1/2 phos-
phorylation in a dose-dependent manner (Figure 4H). Thus,
Rab2A directly binds to Erk1/2 and keeps it in an active form
by competing with MKP3.
To further demonstrate whether this Rab2A-Erk interaction is
functionally important for Rab2A to regulate BCSC, we infected
HMLE cells with Flag-tagged Rab2A or its mutants defective in
binding to Erk (Figure S4C). Rab2A markedly increased the
CD24CD44+ population, but none of its Rab2A mutants altered
this population (Figure S5D). In addition, overexpression of
Rab1A, the small GTPase that is highly related to Rab2A with
over 70% similarity and also localized to the ERGIC but without
a conserved docking motif for binding to Erk, had no effect on
either Erk activation or the BCSC phenotype (Figures S5G–
S5K). Thus, Rab2A directly interacts with and prevents Erk1/2
inactivation by MKP3 to regulate BCSCs.
Rab2A Promotes the Nuclear Translocation of Erk1/2
Downstream b-Catenin
As Erk1/2 signaling increases the nuclear accumulation of un-
phosphorylated (active) b-catenin (Chang et al., 2011), and
because Pin1 also has a similar effect on b-catenin in breast can-
cer cells (Ryo et al., 2001), we examined whether Pin1/Rab2A/
p-Erk signaling regulates nuclear b-catenin levels. Confocal
analysis showed that most unphosphorylated b-catenin local-
ized at the plasma membrane in starved HMLE cells but translo-
cated into the nucleus, along with increased p-Erk1/2 6 hr after
EGF stimulation (Figure 5A). However, in Rab2A-overexpressing
and Pin1-overexpressing cells, not only was p-Erk1/2 obviously
increased but also unphosphorylated b-catenin was readily de-
tected in the nucleus as early as 2 hr and accumulated further
with time after EGF stimulation (Figures 5B and 5C). In contrast,
in Rab2A or Pin1 KD cells, not only was p-Erk1/2 not increased
but also nuclear unphosphorylated b-catenin was hardly detect-
able even 6 hr after stimulation (Figures 5D and 5G). Notably,
overexpression of Rab2A in Pin1 KD cells caused Erk1/2
activation and nuclear translocation and, importantly, unphos-
phorylated b-catenin localization to the nucleus (Figure 5E).
Conversely, Rab2A KD in Pin1-overexpressing cells prevented
Erk1/2 activation and nuclear translocation of unphosphorylated
b-catenin (Figure 5F). Western blot analysis with nuclear fraction
further confirmed these results (Figure 5H). These data together
support a model in which the Pin1/Rab2A/Erk1/2 pathway acti-
vates b-catenin.
Rab2A Endows BCSCTraits to Normal HumanMECs and
Is Necessary for Tumorigenesis of Human Primary
BCSCs
To extend our findings to primary human cells, we sorted Lin
MECs isolated from reduction mammoplasty tissue from two
human donors and infected them with lentiviruses expressing
Flag-Rab2A, Flag-Rab2A Q58H at levels similar to or three times
the endogenous level (Figures 6A and S6A). Rab2A overexpres-
sion led to a dose-dependent increase in the CD24CD44+ pop-118 Cell Reports 11, 111–124, April 7, 2015 ª2015 The Authorsulation (Figure 6B). Overexpressing Rab2A Q58H similar to the
endogenous level increased the CD24CD44+ population more
than overexpressing Rab2A at three-times-higher levels (Fig-
ure 6B). Thus, increasing Rab2A activity by either overexpres-
sion or using naturally occurring cancer-derived mutation
endows BCSC traits to normal human MECs.
To assess whether Rab2A is also important for tumorigenesis
of BCSCs in human primary breast cancer, we sorted
LinCD24CD44+ cells from freshly isolated breast cancer cells
of eight patients (Table S5) and analyzed Rab2A expression and
its impact on BCSCs in vitro and in vivo (Figure S6B). As
compared with those in Linnon-CD24CD44+ cancer cells,
Rab2A mRNA levels were approximately seven times higher in
LinCD24CD44+cells, and five to seven times lower in normal
breast epithelial cells (Figure 6C). Consistent with these results,
Rab2A protein and unphosphorylated b-catenin were higher in
the LinCD24CD44+ cells than those in Linnon-CD24CD44+
cancer cells or normal MECs (Figure 6D). We then knocked
down Rab2A in LinCD24CD44+ primary breast cancer cells
(Figure 6E). The CD24CD44+ population was significantly
reduced in Rab2A KD cells, being only one-ninth of that in con-
trol cells (Figure 6F). Rab2A KD also significantly decreased the
mammosphere-forming activity of the CD24CD44+ cells (Fig-
ures 6G and 6H). Thus, Rab2A is required for sustaining the
BCSC-associated properties of human primary breast cancer
cells.
We finally investigated whether Rab2A was required for the
tumorigenicity of the LinCD24CD44+ population. We injected
2,000 control or Rab2A shRNA-transduced LinCD24CD44+
cells, or Linnon-CD24CD44+ cells isolated from eight breast
cancer patients, into nude mice. While no tumors developed in
mice injected with the cells that were not CD24CD44+, 2,000
control LinCD24CD44+ cells generated six tumors in eight in-
jected mice (Figures 6I–6K). Lentivirus-mediated KD of Rab2A
not only drastically reduced tumor incidence (Figure 6K) but
also potently reduced tumor growth, as measured by tumor vol-
umes and weights (Figures 6I and 6J). We then dissociated the
tumors and sorted again for CD24CD44+ cells for the serial
transplantation. When control tumors were passaged in nude
mice, they were serially transplanted at least for two more pas-
sages without reduced tumorigenicity (Figure 6K), but Rab2A
KD cells had substantially decreased frequency of tumor forma-
tion and reduced tumor growth (Figures 6I–6K). Thus, Rab2A is
highly expressed in BCSC-enriched population in human breast
cancer, and silencing Rab2A potently inhibits BCSC expansion
and tumorigenesis.
Rab2A Overexpression Correlates with Poor Clinical
Outcomes in Breast Cancer Patients
We analyzed expression of Rab2A, Pin1, and ALDH1, a marker
for stem and progenitor cells as well as BCSCs (Ginestier et al.,
2007), in normal and cancerous breast tissue arrays using
immunohistochemistry. Pin1 and Rab2A were undetectable
or low in all 24 human normal breast tissue, but their expres-
sion was dramatically increased in many of 65 human breast
cancer tissue (Figures 7A and 7B). Remarkably, Rab2A expres-
sion was highly correlated with Pin1 and ALDH1 expression in
normal and cancerous breast tissue (Figures 7A–7C). We next
Figure 5. Rab2A/p-Erk Signaling Promotes the Nuclear Translocation of Active b-Catenin
(A and B) Rab2A promoted the nuclear translocation of unphosphorylated b-catenin (active form). HMLE cells were serum starved and then stimulated by EGF for
the indicated time points.
(C–E) Pin1 also promoted the nuclear translocation of unphosphorylated b-catenin and Rab2A overexpression in Pin1 KD cells rescued Erk1/2 activation and
b-catenin translocation from the cell membrane to the nucleus.
(F and G) Rab2A KD in Pin1-overexpressing or vector control cells inhibited p-Erk1/2 activation and b-catenin nuclear translocation. Scale bars represent 10 mm.
(H) Rab2A promoted the nuclear accumulation of p-Erk1/2 and unphosphorylated b-catenin. Nuclear and total proteins were extracted after EGF stimulation
following serum starvation.analyzed the correlation of Rab2A expression and clinical
outcome in the subset of 52 breast cancer patients, for which
clinical data were available. Higher Rab2A expression was
significantly associated with higher mortality in breast cancer
patients, as shown by Kaplan-Meier survival curves (p =
0.012) (Figure 7D).
To expand our immunohistochemistry findings on limited sam-
ples, we studied multiple independent breast cancer datasets
from Oncomine (Rhodes et al., 2007), which collectively link clin-
ical data with Rab2A mRNA expression in 3,000 patients.
Rab2A overexpression was closely associated with advanced
stage in the Bittner dataset, with metastasis in the Schmidt data-
set, and with death at 3 or 5 years in the Bild and Kao datasets(Bild et al., 2006; Kao et al., 2011; Schmidt et al., 2008) (Figures
S7A–S7D).
Giving that the microarray experiments and the methods to
normalize data vary among different datasets, making it difficult
to pool the data from different datasets, we chose to further
analyze the Curtis dataset, which has over 2,000 patients (Curtis
et al., 2012). The Rab2A mRNA level was a strong prognostic
factor for survival by univariate Cox regression analysis (Fig-
ure 7E). A high Rab2A level was still independently associated
with high mortality, even using multivariate analysis adjusted
for proliferation markers (MKI67 and PCNA), or tumor grade
and stage, or the status of HER2, ER, and PR (Figure 7E).
We next analyzed Rab2A expression in the PAM50 intrinsicCell Reports 11, 111–124, April 7, 2015 ª2015 The Authors 119
Figure 6. Rab2A and Its Q58H Mutant Endow BCSC Traits to Normal Primary Human MECs, whereas Silencing Rab2A Inhibits Primary
Human BCSC Expansion and Tumorigenesis
(A) Western blot showed lentivirus-mediated overexpression of Rab2A and Q58Hmutant in two cases of human normal LinMECs. Arrowhead, exogenous Flag
tagged protein; arrow, endogenous protein.
(B) Rab2A or Rab2A Q58H mutant increased the CD24CD44+ population in primary human MECs.
(C) Real-time PCR showed that expression of Rab2AmRNAwasmarkedly increased in the LinCD24CD44+ population, compared to Linnon-CD24CD44+ or
normal epithelial cells.
(D) Expression of Rab2A and unphosphorylated b-catenin protein wasmarkedly increased in LinCD24CD44+ cells compared to Linnon-CD24CD44+ cells in
human breast cancer tissue and those in normal breast tissue from the same patient.
(E) Rab2A was knocked down in LinCD24CD44+ cells sorted from human breast cancer tissue.
(F) Rab2A KD in LinCD24CD44+ breast cancer cells decreased the CD24CD44+ population.
(G and H) Rab2A KD in LinCD24CD44+ breast cancer cells decreased mammosphere formation. Scale bar represents 100 mm.
(I–K) Rab2A KD interfered with both tumor initiation and growth of primary BCSCs in vivo, as shown by tumor growth curve (I), tumor weights (J), and tumor
incidence (K). 2,000 lentivirus-transduced LinCD24CD44+ cells isolated from eight breast cancer patients were serially transplanted as xenografts into eight
nude mice. P0, freshly isolated primary cells; P1, passage 1; P2, passage 2.
In (C) and (H), error bars represent SD of three independent experiments. In (I) and (J), error bars represent SD of eight mice. See also Figure S6.subtypes (Parker et al., 2009) and integrative subgroups (Curtis
et al., 2012). Strikingly, high Rab2A levels were found in the
poor-prognosis subtypes, defined as PAM50 intrinsic subtypes,
luminal B, HER2-enriched, and basal-like, and in the IntClust5,
IntClust6, IntClust9, and IntClust10 integrative subgroups (Fig-
ures 7F and 7G), whereas low Rab2A levels were mostly
observed in the better-prognosis subtypes (normal-like PAM50
intrinsic subtype and integrative subgroups IntClust3 and
IntClust4) (Figures 7F and 7G). Notably, a high Rab2A level
was tightly linked to high mortality in the most common sub-
groups of breast cancer patients, defined as HER2-negative or
non-TNBC (triple-negative) patients (Figure 7H), which account
for 87.5% and 87.3% of all cases, respectively. Thus, Rab2A
plays a key oncogenic role in promoting BCSCs and aggravating
breast cancer malignancy.120 Cell Reports 11, 111–124, April 7, 2015 ª2015 The AuthorsDISCUSSION
Our profiling of Pin1-regulated genes led to the discovery that
Pin1 promotes BCSCs by increasing Rab2A transcription. We
suggest that in breast cancer, Pin1 overexpression, Rab2A
gene amplification, or genetic mutation activates Rab2A, which
drives BCSCs and tumorigenesis in large part by preventing
Erk1/2 inactivation via MKP3, leading to activation of known
BCSC regulators and contributing to highmortality in breast can-
cer patients (Figure 7I). This pathway may offer attractive BCSC
targets for cancer therapy. Notably, ATRA has been identified to
bind and ultimately degrade active Pin1 selectively in cancer
cells (data not shown).
Emerging evidence has shown that Rab family members
play important roles in epithelial neoplasia (Goldenring, 2013).
Figure 7. Rab2A Expression Correlates with Pin1 and ALDH1 Expression and with Poor Clinical Outcome in Breast Cancer Patients
(A–C) Rab2A expression correlated with Pin1 and ALDH1 expression in the tissue array of normal and cancerous breast tissue.
(D) High Rab2A expression correlated with poor overall survival in the tissue array dataset of breast cancer patients.
(E) Rab2A was a strong and independent biomarker to predict breast cancer specific survival in the Curtis breast cancer dataset by Cox regression analyses.
(F) Boxplots of Rab2A expression stratified by the PAM50 classifier in the Curtis breast cancer dataset.
(G) Boxplots of Rab2A expression stratified by the IntClust subtypes in the Curtis breast cancer dataset.
(legend continued on next page)
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Although Rab25 has opposing functions in cancer, promoting tu-
mor aggressiveness (Cheng et al., 2004) and suppressing tumor
development (Nam et al., 2010; Tong et al., 2012), most Rab
members with increased expression in cancer are positively
associated with cancer progression, especially with invasion
and metastasis (Hou et al., 2008; Jacob et al., 2013). We report
here that Rab2A plays a major oncogenic role in human breast
cancer via promoting BCSC expansion and tumorigenicity.
Furthermore, we have provided strong genetic evidence that
Rab2A is abnormally activated in human cancer by either gene
amplification or activating Rab2A point mutation, both of which
enhance its ability to activate Erk1/2 signaling. Finally, gene
expression profiling data in five large datasets containing
3,000 breast cancer patients strongly link Rab2A to poor pa-
tient outcome. Notably, in the >2,000-patient Curtis dataset,
high Rab2A levels were found in poor-prognosis subtypes,
whereas low Rab2A levels were mostly observed in better-prog-
nosis subtypes. Significantly, a high Rab2A level was strongly
associated with high mortality, even in multivariate analysis. It
is worth noting that the association between Rab2A and cancer
mortality was even more striking in the most common groups
(87%) of breast cancer patients, defined as HER2-negative
or non-TNBC patients. Since it is challenging to predict poor
prognosis in these common subgroups of breast cancer patients
without profilingmany genes, Rab2A expressionmight represent
a useful prognosis biomarker.
Rab2A has previously been implicated in intercellular vesicle
trafficking regulation (Stenmark, 2009; Tisdale and Balch,
1996). Our findings highlight the role of Rab GTPases in altering
cell signaling. Previously, Rab5was shown to transduce cell-sur-
vival signals by facilitating vesicular translocation to the nucleus
of multiple signaling kinases in neurons, including Akt and Erk
(Delcroix et al., 2003). The endosomal Rab23 is an essential
negative regulator that attenuates the mouse sonic hedgehog
signaling pathway downstream of the sonic hedgehog receptor
and its effector (Eggenschwiler et al., 2001). Our results that
Erk signaling is critical for Rab2A to regulate BCSCs are reminis-
cent of previous reports showing that the Erk pathway is required
for BCSC maintenance. For example, Ras signals through the
Erk pathway (Chiu et al., 2002), and Erk2 activation is essential
for Ras to induce the EMT and to promote the CD24CD44+
population (Shin et al., 2010). SHP2 influences BCSCs and
enhances breast tumor maintenance and progression through
activation of the Erk pathway (Aceto et al., 2012).
It is interesting to note that the docking motif in Erk1/2 is com-
mon to its activators, substrates, and regulators, suggesting that
they may compete for binding to Erk1/2 in vivo (Bardwell et al.,
2003; Tanoue et al., 2000). Indeed, these docking interactions
are crucial for the specificity of Erk1/2 signaling and the duration
of the activation-inactivation cycles of Erk1/2. In the absence of
activation, Erk1/2 is mainly localized to the cytoplasm. Activated
Erk1/2 translocates to the nucleus and phosphorylates nuclear
targets. MKP3 shuttles between the cytoplasm and nucleus(H) Univariate Cox regression analysis showed that HER2-negative, non-triple-neg
mRNA levels had a higher risk of breast cancer mortality.
(I) A schematic model for how the Pin1/Rab2A/Erk signal pathway regulates tum
See also Figure S7.
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It is possible that Erk1/2 bound by Rab2A is temporarily pro-
tected from the action of the phosphatase MKP3. Thus, the
competitive docking of Rab2A and phosphatase to Erk1/2 may
play an important role in enhancing Erk signaling. Moreover,
we found that Erk1/2 and Rab2A colocalized at the ERGIC.
Although Erk3 is principally localized to the Golgi and ERGIC in
several cell lines (Bind et al., 2004), the role of Erks at the ERGIC
is largely unknown. It would be interesting to define the molecu-
lar details of the Erk1/2 and Rab2A interactions and their regula-
tion at the ERGIC for Erk signaling.
Small GTPases act through cycling between an active, GTP-
bound and an inactive, GDP-bound state. Activating Ras muta-
tions occur in 30% of human cancers. Most of the activating
mutations impair intrinsic GTPase activity or confer resistance
to GTPase activating proteins (GAPs), causing mutant Ras to
accumulate in the active GTP-bound form (Schubbert et al.,
2007). The Rab2A Q58H mutation, a naturally occurring genetic
mutation found in human cancers, not only reduced GTP hy-
drolysis but also was more potent in activating Erk signaling
and driving BCSCs than the WT protein. Therefore, the Q58H
protein might be a hyperactive form of Rab2A in human
cancers.
EXPERIMENTAL PROCEDURES
Microarray Analysis
RNA from LinMECs and neuron cells of Pin1 KO andWTmice was extracted
with the total RNA isolation kit (Agilent). Microarray expression profiles were
collected using Affymetrix GeneChip Mouse Expression Array 430A.
Serial Transplantation Assay
LinCD24CD44+ cells were sorted from eight breast cancer specimens and
cultured as a single-cell suspension in ultra-low-attachment dishes, then in-
fected with lentivirus expressing control vector or Rab2A shRNA. After
1 week of puromycin selection, 2,000 transduced cells from each patient
were injected into the mammary fat pads of 5-week-old nude mice. For
serial passaging, cells from the primary tumors were sorted again for
LinCD24CD44+ cells. Among the six primary tumors formed in the control
shRNA group, four tumors were randomly selected and passaged into eight
mice (two mice per tumor). For the one tumor formed from 2,000 shRab2A
cells, this tumor’s cells were injected into eight mice for serial passaging.
The same procedure was applied to the second passage of xenograft cells,
as described previously (Yu et al., 2007). All studies involving human subjects
were approved by the institutional review board at Beth Israel Deaconess
Medical Center or Sun Yat-Sen Memorial Hospital. All studies involving mice
were approved by the institutional animal care and use committee at Beth
Israel Deaconess Medical Center and performed in accordance with the rele-
vant protocols.
Statistical Analysis
All data are presented as the means ± SD, followed by determining significant
differences using the two-tailed t test or ANOVA test. Limiting-dilution data
were analyzed by the single-hit Poisson model using a complementary log-
log generalized linear model (Bonnefoix et al., 2001) with L-Calc Software
(STEMCELL Technologies). Correlations of Rab2A expression with other
gene expression were analyzed with the Pearson correlation test. For survivalative, or PAM50-normal subtypes of breast cancer patients with higher Rab2A
or initiation via CSC regulators, contributing to high mortality in breast cancer.
analysis, Kaplan-Meier analysis and univariate andmultivariate Cox regression
analysis were used. All tests of significance were set at p < 0.05.
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